Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Redx Pharma Yönetim
Yönetim kriter kontrolleri 3/4
Redx Pharma's CEO is Lisa Mary Anson, appointed in Jun 2018, has a tenure of 5.92 years. total yearly compensation is £608.13K, comprised of 94.9% salary and 5.1% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth £112.75K. The average tenure of the management team and the board of directors is 3 years and 3 years respectively.
Anahtar bilgiler
Lisa Mary Anson
İcra Kurulu Başkanı
UK£608.1k
Toplam tazminat
| CEO maaş yüzdesi | 94.9% |
| CEO görev süresi | 5.9yrs |
| CEO sahipliği | 0.2% |
| Yönetim ortalama görev süresi | 3yrs |
| Yönetim Kurulu ortalama görev süresi | 3yrs |
CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2023 | UK£608k | UK£577k | -UK£33m |
| Jun 30 2023 | n/a | n/a | -UK£31m |
| Mar 31 2023 | n/a | n/a | -UK£29m |
| Dec 31 2022 | n/a | n/a | -UK£24m |
| Sep 30 2022 | UK£637k | UK£606k | -UK£18m |
| Jun 30 2022 | n/a | n/a | -UK£18m |
| Mar 31 2022 | n/a | n/a | -UK£19m |
| Dec 31 2021 | n/a | n/a | -UK£20m |
| Sep 30 2021 | UK£2m | UK£615k | -UK£22m |
| Jun 30 2021 | n/a | n/a | -UK£20m |
| Mar 31 2021 | n/a | n/a | -UK£18m |
| Dec 31 2020 | n/a | n/a | -UK£14m |
| Sep 30 2020 | UK£619k | UK£481k | -UK£9m |
| Jun 30 2020 | n/a | n/a | -UK£8m |
| Mar 31 2020 | n/a | n/a | -UK£6m |
| Dec 31 2019 | n/a | n/a | -UK£5m |
| Sep 30 2019 | UK£439k | UK£390k | -UK£4m |
| Jun 30 2019 | n/a | n/a | -UK£5m |
| Mar 31 2019 | n/a | n/a | -UK£7m |
| Dec 31 2018 | n/a | n/a | -UK£8m |
| Sep 30 2018 | UK£372k | UK£100k | -UK£9m |
Tazminat ve Piyasa: Lisa Mary's total compensation ($USD759.28K) is above average for companies of similar size in the UK market ($USD344.28K).
Tazminat ve Kazançlar: Lisa Mary's compensation has been consistent with company performance over the past year.
CEO
Lisa Mary Anson (55 yo)
5.9yrs
Görev süresi
UK£608,127
Tazminat
Mrs. Lisa Mary Whewell Anson serves as the Chief Executive Officer and Executive Director at Redx Pharma PLC since June 1, 2018. She has been President of AstraZeneca UK since 2012 and brings significant l...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Executive Director | 5.9yrs | UK£608.13k | 0.19% £ 112.8k | |
| Chief Financial Officer | 3yrs | Veri yok | Veri yok | |
| Chief Operating Officer | 3yrs | UK£210.91k | Veri yok | |
| Chief Scientific Officer | 10.3yrs | Veri yok | Veri yok | |
| Head of Investor Relations | no data | Veri yok | Veri yok | |
| General Counsel & Company Secretary | 2.3yrs | Veri yok | Veri yok | |
| Head of Communications | 2.1yrs | Veri yok | Veri yok | |
| Senior Vice President of Chemistry | 8.3yrs | Veri yok | Veri yok | |
| Senior Vice President of Biology | no data | Veri yok | Veri yok | |
| Head of Development Operations | no data | Veri yok | Veri yok | |
| Head of Nonclinical Development | 3.3yrs | Veri yok | Veri yok | |
| Interim Chief Medical Officer | less than a year | Veri yok | Veri yok |
3.0yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: REDX's management team is considered experienced (3 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Executive Director | 5.9yrs | UK£608.13k | 0.19% £ 112.8k | |
| Independent Non-Executive Director | 6.5yrs | UK£48.75k | 0.038% £ 21.9k | |
| Non-Executive Director | less than a year | Veri yok | Veri yok | |
| Independent Non-Executive Director | 8.3yrs | UK£49.00k | Veri yok | |
| Independent Non-Executive Chair | 2.4yrs | UK£85.00k | 0.022% £ 12.7k | |
| Independent Non-Executive Director | 2.3yrs | UK£41.50k | Veri yok | |
| Shareholder Representative Non-Executive Director | 3yrs | Veri yok | Veri yok |
3.0yrs
Ortalama Görev Süresi
65yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: REDX's board of directors are considered experienced (3 years average tenure).